ArticleACS applied materials & interfaces2022
Plasmonic Metasurfaces for Specific SERS Detection of Shiga Toxins.
Article in ACS applied materials & interfaces, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Recent Advancements in the SERS-Based Detection ofSensors (Basel, Switzerland) · 2026Review
- Single-Exosome SERS Detection by Means of a Flexible Metasurface.Biosensors · 2025Article
- Advancing Medical Diagnostics: Rapid, Label-Free Detection and Differentiation of Shiga Toxin Variants in Human Serum Using a Cost-Effective PCA-Assisted SERS Platform.ACS applied materials & interfaces · 2025Article
- Diagnostic oriented discrimination of different Shiga toxins via PCA-assisted SERS-based plasmonic metasurface.Nanophotonics (Berlin, Germany) · 2025Article
- Review
- Enhancing Shiga toxin detection using surface plasmon resonance a study of antibody immobilization strategies.Scientific reports · 2025Article
- Advances in Multifunctional Nanoagents and SERS-Based Multimodal Sensing for Biotoxin in Foods.Foods (Basel, Switzerland) · 2025Review
- Deep Learning-Assisted SERS for Therapeutic Drug Monitoring of Clozapine in Serum on Plasmonic Metasurfaces.Nano letters · 2025Article
- Nanostructured Surfaces with Plasmonic Activity and Superhydrophobicity: Review of Fabrication Strategies and Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Biosensors for Seafood Safety Control-A Review.Micromachines · 2024Review
- Advancements and Perspectives in Optical Biosensors.ACS omega · 2024Review
- The Label-Free Detection and Identification of SARS-CoV-2 Using Surface-Enhanced Raman Spectroscopy and Principal Component Analysis.Biosensors · 2023Article
- Self-Assembly of Silver Nanowire Films for Surface-Enhanced Raman Scattering Applications.Nanomaterials (Basel, Switzerland) · 2023Article
- Latest Advances in Metasurfaces for SERS and SEIRA Sensors as Well as Photocatalysis.International journal of molecular sciences · 2022Review
- Transcription Factor-Based Biosensors for Detecting Pathogens.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interest in the development of nanoscale plasmonic technologies has dramatically increased in recent years. The photonic properties of plasmonic nanopatterns can be controlled and tuned via their size, shape, or the arrangement of their constituents. In this work, we propose a 2D hybrid metallic polymeric nanostructure based on the octupolar framework with enhanced sensing property. We analyze its plasmonic features both numerically and experimentally, demonstrating the higher values of their relevant figures of merit: we estimated a surface-enhanced Raman spectroscopy (SERS) enhancement factor of 9 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.